Pulmonary Embolism Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology  

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pulmonary Embolism Market 

5.1. COVID-19 Landscape: Pulmonary Embolism Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pulmonary Embolism Market, By Treatment Type

8.1. Pulmonary Embolism Market Revenue and Volume, by Treatment Type

8.1.1. Anticoagulants

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Thrombolytics

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Mechanical Thrombectomy

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Pulmonary Embolism Market, By Patient Population

9.1. Pulmonary Embolism Market Revenue and Volume, by Patient Population

9.1.1. Patients with Symptomatic Pulmonary Embolism

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Patients with Asymptomatic Pulmonary Embolism

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Patients with High-Risk Pulmonary Embolism

9.1.3.1. Market Revenue and Volume Forecast

Chapter 10. Global Pulmonary Embolism Market, By Drug Route Administration 

10.1. Pulmonary Embolism Market Revenue and Volume, by Drug Route Administration

10.1.1. Intravenous 

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Subcutaneous 

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Oral

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Pulmonary Embolism Market, By Drug Type

11.1. Pulmonary Embolism Market Revenue and Volume, by Drug Type

11.1.1. Direct Oral Anticoagulants (DOACs)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Heparins

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Vitamin K Antagonists

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Pulmonary Embolism Market, By End-Use Sector

12.1. Pulmonary Embolism Market Revenue and Volume, by End-Use Sector

12.1.1. Hospitals

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Clinics

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Ambulatory Surgical Centers

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global Pulmonary Embolism Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.2. Market Revenue and Volume Forecast, by Patient Population

13.1.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.1.4. Market Revenue and Volume Forecast, by Drug Type

13.1.5. Market Revenue and Volume Forecast, by End-Use Sector

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.6.2. Market Revenue and Volume Forecast, by Patient Population

13.1.6.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.1.6.4. Market Revenue and Volume Forecast, by Drug Type

13.1.6.5. Market Revenue and Volume Forecast, by End-Use Sector  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Treatment Type

13.1.7.2. Market Revenue and Volume Forecast, by Patient Population

13.1.7.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.1.7.4. Market Revenue and Volume Forecast, by Drug Type

13.1.7.5. Market Revenue and Volume Forecast, by End-Use Sector

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.2. Market Revenue and Volume Forecast, by Patient Population

13.2.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.2.4. Market Revenue and Volume Forecast, by Drug Type  

13.2.5. Market Revenue and Volume Forecast, by End-Use Sector  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.6.2. Market Revenue and Volume Forecast, by Patient Population

13.2.6.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.2.7. Market Revenue and Volume Forecast, by Drug Type  

13.2.8. Market Revenue and Volume Forecast, by End-Use Sector  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.9.2. Market Revenue and Volume Forecast, by Patient Population

13.2.9.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.2.10. Market Revenue and Volume Forecast, by Drug Type

13.2.11. Market Revenue and Volume Forecast, by End-Use Sector

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.12.2. Market Revenue and Volume Forecast, by Patient Population

13.2.12.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.2.12.4. Market Revenue and Volume Forecast, by Drug Type

13.2.13. Market Revenue and Volume Forecast, by End-Use Sector

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Treatment Type

13.2.14.2. Market Revenue and Volume Forecast, by Patient Population

13.2.14.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.2.14.4. Market Revenue and Volume Forecast, by Drug Type

13.2.15. Market Revenue and Volume Forecast, by End-Use Sector

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.2. Market Revenue and Volume Forecast, by Patient Population

13.3.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.3.4. Market Revenue and Volume Forecast, by Drug Type

13.3.5. Market Revenue and Volume Forecast, by End-Use Sector

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.6.2. Market Revenue and Volume Forecast, by Patient Population

13.3.6.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.3.6.4. Market Revenue and Volume Forecast, by Drug Type

13.3.7. Market Revenue and Volume Forecast, by End-Use Sector

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.8.2. Market Revenue and Volume Forecast, by Patient Population

13.3.8.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.3.8.4. Market Revenue and Volume Forecast, by Drug Type

13.3.9. Market Revenue and Volume Forecast, by End-Use Sector

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.10.2. Market Revenue and Volume Forecast, by Patient Population

13.3.10.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.3.10.4. Market Revenue and Volume Forecast, by Drug Type

13.3.10.5. Market Revenue and Volume Forecast, by End-Use Sector

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.3.11.2. Market Revenue and Volume Forecast, by Patient Population

13.3.11.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.3.11.4. Market Revenue and Volume Forecast, by Drug Type

13.3.11.5. Market Revenue and Volume Forecast, by End-Use Sector

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.2. Market Revenue and Volume Forecast, by Patient Population

13.4.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.4.4. Market Revenue and Volume Forecast, by Drug Type

13.4.5. Market Revenue and Volume Forecast, by End-Use Sector

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.6.2. Market Revenue and Volume Forecast, by Patient Population

13.4.6.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.4.6.4. Market Revenue and Volume Forecast, by Drug Type

13.4.7. Market Revenue and Volume Forecast, by End-Use Sector

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.8.2. Market Revenue and Volume Forecast, by Patient Population

13.4.8.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.4.8.4. Market Revenue and Volume Forecast, by Drug Type

13.4.9. Market Revenue and Volume Forecast, by End-Use Sector

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.10.2. Market Revenue and Volume Forecast, by Patient Population

13.4.10.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.4.10.4. Market Revenue and Volume Forecast, by Drug Type

13.4.10.5. Market Revenue and Volume Forecast, by End-Use Sector

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Treatment Type

13.4.11.2. Market Revenue and Volume Forecast, by Patient Population

13.4.11.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.4.11.4. Market Revenue and Volume Forecast, by Drug Type

13.4.11.5. Market Revenue and Volume Forecast, by End-Use Sector

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.2. Market Revenue and Volume Forecast, by Patient Population

13.5.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.5.4. Market Revenue and Volume Forecast, by Drug Type

13.5.5. Market Revenue and Volume Forecast, by End-Use Sector

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.6.2. Market Revenue and Volume Forecast, by Patient Population

13.5.6.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.5.6.4. Market Revenue and Volume Forecast, by Drug Type

13.5.7. Market Revenue and Volume Forecast, by End-Use Sector

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Treatment Type

13.5.8.2. Market Revenue and Volume Forecast, by Patient Population

13.5.8.3. Market Revenue and Volume Forecast, by Drug Route Administration

13.5.8.4. Market Revenue and Volume Forecast, by Drug Type

13.5.8.5. Market Revenue and Volume Forecast, by End-Use Sector

Chapter 14. Company Profiles

14.1. Aspen Holdings

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. AstraZeneca

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Boehringer Ingelheim International GmbH

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Bristol Myers Squibb Company

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. F. Hoffmann-La Roche Ltd.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Fresenius Kabi AG

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. GlaxoSmithKline plc

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Johnson & Johnson Private Limited

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Merck & Co., Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms